Lv7
4990 积分 2022-05-13 加入
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
4个月前
已完结
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
4个月前
已完结
Mechanisms governing lineage plasticity and metabolic reprogramming in cancer
6个月前
已完结
USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity
1年前
已完结
Expression Pattern of Plexin Domain Containing 2 in Human Hepatocellular Carcinoma
1年前
已完结
Discontinuation of Immune-oncology Combinations due to Immune-related Adverse Events in Patients With Advanced Renal Cancers
1年前
已完结
Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments
1年前
已完结
Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL‐17 signaling pathway gene LCN2 in castration‐resistant prostate cancer
1年前
已完结
Diabetes, Obesity, and Pathologic Upstaging in Renal Cell Carcinoma: Results from a large multi-institutional consortium
2年前
已完结
Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies
2年前
已完结
皖公网安备34019202002308
